MX2020001083A - Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. - Google Patents
Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.Info
- Publication number
- MX2020001083A MX2020001083A MX2020001083A MX2020001083A MX2020001083A MX 2020001083 A MX2020001083 A MX 2020001083A MX 2020001083 A MX2020001083 A MX 2020001083A MX 2020001083 A MX2020001083 A MX 2020001083A MX 2020001083 A MX2020001083 A MX 2020001083A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acids
- treatment
- compositions including
- diseases related
- including amino
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004065 mitochondrial dysfunction Effects 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000001630 malic acid Substances 0.000 abstract 1
- 235000011090 malic acid Nutrition 0.000 abstract 1
- 230000008437 mitochondrial biogenesis Effects 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Composición para promover la biogénesis mitocondrial y mejorar la función mitocondrial en un sujeto, la composición comprende un agente activo, dicho agente activo que contiene los aminoácidos leucina, isoleucina, valina, treonina, lisina y ácido cítrico, ácido succínico, ácido málico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102017000087359A IT201700087359A1 (it) | 2017-07-28 | 2017-07-28 | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| PCT/IB2018/055425 WO2019021135A1 (en) | 2017-07-28 | 2018-07-20 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020001083A true MX2020001083A (es) | 2022-08-31 |
| MX395240B MX395240B (es) | 2025-03-25 |
Family
ID=60628070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001083A MX395240B (es) | 2017-07-28 | 2018-07-20 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
| MX2022010774A MX2022010774A (es) | 2017-07-28 | 2020-01-27 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010774A MX2022010774A (es) | 2017-07-28 | 2020-01-27 | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11337946B2 (es) |
| EP (2) | EP3915553B1 (es) |
| JP (2) | JP7266767B2 (es) |
| KR (3) | KR20230117642A (es) |
| CN (1) | CN110996935A (es) |
| AU (2) | AU2018306540B2 (es) |
| BR (1) | BR112020001471A2 (es) |
| CA (1) | CA3070197C (es) |
| CL (1) | CL2020000220A1 (es) |
| DK (2) | DK3915553T3 (es) |
| ES (2) | ES3031608T3 (es) |
| HU (1) | HUE059050T2 (es) |
| IT (1) | IT201700087359A1 (es) |
| LT (1) | LT3658132T (es) |
| MX (2) | MX395240B (es) |
| MY (1) | MY200975A (es) |
| PH (1) | PH12020500190A1 (es) |
| PL (2) | PL3915553T3 (es) |
| PT (2) | PT3658132T (es) |
| RS (1) | RS63422B1 (es) |
| SG (1) | SG11201912103TA (es) |
| WO (1) | WO2019021135A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700087359A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT201900002109A1 (it) * | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| JP2021038147A (ja) * | 2019-08-30 | 2021-03-11 | 国立大学法人 鹿児島大学 | ミトコンドリア生合成促進剤 |
| IT202000000442A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| IT202000000454A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
| CA3167119A1 (en) * | 2020-04-01 | 2021-10-07 | Claudia Roessle | Compositions containing amino acids and methods of using such compositions for treating sarcopenia |
| IT202000021664A1 (it) * | 2020-09-14 | 2022-03-14 | Iaf Network S P A | Formulazione amminoacidica bilanciata |
| TW202308604A (zh) * | 2021-05-10 | 2023-03-01 | 國立大學法人東北大學 | 肌肉量增加用組成物 |
| IT202100029726A1 (it) | 2021-11-24 | 2023-05-24 | Professional Dietetics Spa | Composizioni oftalmiche per il trattamento di lesioni corneali |
| KR20250035239A (ko) | 2023-09-05 | 2025-03-12 | 메디컬아이피 주식회사 | 의료영상 내 관형구조물의 직경파악방법 및 그 장치 |
| CN120661636A (zh) * | 2025-06-12 | 2025-09-19 | 中国医学科学院医学实验动物研究所 | 一种胞质特异性表达ppm1k的基因递送系统及其制备方法和应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| ITTO20010580A1 (it) * | 2001-06-15 | 2002-12-15 | Professional Dietetics Srl | Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete. |
| ITTO20010804A1 (it) | 2001-08-08 | 2003-02-08 | Professional Dietetics Srl | Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl |
| US6620850B2 (en) | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| ITTO20030789A1 (it) | 2003-10-07 | 2005-04-08 | Professional Dietetics Srl | Composizione a base di amino acidi per il trattamento |
| WO2007049818A1 (ja) | 2005-10-27 | 2007-05-03 | Ajinomoto Co., Inc. | 抗脂肪肝、抗肥満及び抗高脂血症用組成物 |
| US7982066B2 (en) * | 2005-12-09 | 2011-07-19 | Novalife, Inc. | High protein supplement |
| JP2007161642A (ja) | 2005-12-14 | 2007-06-28 | Kyowa Hakko Kogyo Co Ltd | アルコール性肝障害抑制剤 |
| TWI551288B (zh) | 2011-02-17 | 2016-10-01 | Ea Pharma Co Ltd | Antimicrobial activity enhancer for chemotherapeutic agents |
| JPWO2012147901A1 (ja) | 2011-04-28 | 2014-07-28 | 味の素株式会社 | 抗癌剤副作用改善用組成物 |
| US20130084378A1 (en) | 2011-09-30 | 2013-04-04 | Daesang Corporation | Amino acid seasoning compositions comprising l-glutamic acid and l-lysine |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US20160038565A1 (en) | 2012-06-15 | 2016-02-11 | Gencia Corporation | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy |
| CN102772407B (zh) | 2012-08-01 | 2014-09-17 | 岳茂兴 | 一种促进神经损伤修复的药物组合物及其应用 |
| US9597367B2 (en) * | 2013-04-19 | 2017-03-21 | Bioventures, Llc | Methods for improving muscle and heart function |
| EP3231437B1 (en) | 2014-12-09 | 2020-02-05 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
| MX357998B (es) * | 2015-03-20 | 2018-07-11 | Antonio Hernandez Miramontes Jorge | Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. |
| US20180161296A1 (en) | 2015-05-11 | 2018-06-14 | Newcastle Innovation Limited | Amino acid supplementation |
| ES2779749T3 (es) | 2015-05-14 | 2020-08-19 | Professional Dietetics Int Srl | Composiciones que comprenden aminoácidos para uso en el tratamiento de mucositis en pacientes con neoplasia que están sometidos a radioterapia y/o quimioterapia |
| WO2017020121A1 (en) | 2015-07-31 | 2017-02-09 | Val-Chum, Limited Partnership | Glycerol-3-phosphate phosphatase activators |
| US20180344677A1 (en) | 2015-11-27 | 2018-12-06 | Doublegood Ab | Food supplement and composition for treating the metabolic syndrome |
| CN110678172A (zh) | 2017-04-28 | 2020-01-10 | 胺细拉健康公司 | 用于治疗创伤性脑损伤的氨基酸组合物及其使用方法 |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087359A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| CA3078335A1 (en) | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | Materials and methods for inhibiting tumor growth |
| WO2019172287A1 (ja) * | 2018-03-05 | 2019-09-12 | 味の素株式会社 | 認知機能の改善用組成物および不安様症状の改善用組成物、ならびに脳萎縮の抑制用組成物 |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| US12137359B2 (en) | 2019-11-11 | 2024-11-05 | Lg Electronics Inc. | Vehicular distributed antenna system operating in wireless communication system and method for operating same |
| IT202000000454A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| WO2022266480A1 (en) | 2021-06-17 | 2022-12-22 | Axcella Health Inc. | Methods of predicting liver fat content and uses thereof |
-
2017
- 2017-07-28 IT IT102017000087359A patent/IT201700087359A1/it unknown
-
2018
- 2018-07-20 KR KR1020237026054A patent/KR20230117642A/ko not_active Ceased
- 2018-07-20 LT LTEPPCT/IB2018/055425T patent/LT3658132T/lt unknown
- 2018-07-20 MY MYPI2020000106A patent/MY200975A/en unknown
- 2018-07-20 MX MX2020001083A patent/MX395240B/es unknown
- 2018-07-20 AU AU2018306540A patent/AU2018306540B2/en active Active
- 2018-07-20 PL PL21174744.9T patent/PL3915553T3/pl unknown
- 2018-07-20 RS RS20220627A patent/RS63422B1/sr unknown
- 2018-07-20 WO PCT/IB2018/055425 patent/WO2019021135A1/en not_active Ceased
- 2018-07-20 CN CN201880047542.0A patent/CN110996935A/zh active Pending
- 2018-07-20 JP JP2019566579A patent/JP7266767B2/ja active Active
- 2018-07-20 EP EP21174744.9A patent/EP3915553B1/en active Active
- 2018-07-20 ES ES21174744T patent/ES3031608T3/es active Active
- 2018-07-20 PT PT187534656T patent/PT3658132T/pt unknown
- 2018-07-20 DK DK21174744.9T patent/DK3915553T3/da active
- 2018-07-20 KR KR1020207003492A patent/KR102566297B1/ko active Active
- 2018-07-20 DK DK18753465.6T patent/DK3658132T3/da active
- 2018-07-20 KR KR1020247014645A patent/KR20240063205A/ko not_active Ceased
- 2018-07-20 US US16/634,330 patent/US11337946B2/en active Active
- 2018-07-20 ES ES18753465T patent/ES2923126T3/es active Active
- 2018-07-20 SG SG11201912103TA patent/SG11201912103TA/en unknown
- 2018-07-20 PT PT211747449T patent/PT3915553T/pt unknown
- 2018-07-20 BR BR112020001471-0A patent/BR112020001471A2/pt unknown
- 2018-07-20 CA CA3070197A patent/CA3070197C/en active Active
- 2018-07-20 EP EP18753465.6A patent/EP3658132B1/en active Active
- 2018-07-20 HU HUE18753465A patent/HUE059050T2/hu unknown
- 2018-07-20 PL PL18753465.6T patent/PL3658132T3/pl unknown
-
2020
- 2020-01-27 MX MX2022010774A patent/MX2022010774A/es unknown
- 2020-01-27 CL CL2020000220A patent/CL2020000220A1/es unknown
- 2020-01-27 PH PH12020500190A patent/PH12020500190A1/en unknown
-
2022
- 2022-04-20 US US17/724,537 patent/US11957651B2/en active Active
-
2023
- 2023-03-08 JP JP2023035509A patent/JP7513311B2/ja active Active
- 2023-11-14 AU AU2023266256A patent/AU2023266256B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001083A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| MX395112B (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| CL2020003209A1 (es) | Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| EA202090890A1 (ru) | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия | |
| CL2022001779A1 (es) | Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer | |
| CL2019003670A1 (es) | Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta. | |
| AR109799A1 (es) | Composición para el tratamiento del cabello | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| CL2021002131A1 (es) | Uso de composiciones con aminoácidos para el tratamiento de lesiones del sistema nervioso central. | |
| AR097216A1 (es) | Composición para el tratamiento contra el envejecimiento de la piel | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
| MX2019008961A (es) | Composicion intranasal que comprende betahistina. | |
| MX389461B (es) | Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos | |
| MX2021005807A (es) | Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides. | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| NZ728962A (en) | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia | |
| PH12016501448A1 (en) | Antifungal composition | |
| TH2001000484A (th) | องค์ประกอบซึ่งประกอบรวมด้วยกระอะมิโนสำหรับใช้ในการรักษาโรคที่เกี่ยวข้องกับการทำหน้าที่ผิดปกติของไมโครทอนเดรีย |